Levoleucovorin calcium for autism spectrum disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 16 Aug 2019: Trial registered, NCT04060017
  2. 16 Aug 2019: Trial registered, NCT04060030
  3. 22 Sep 2020: Trial started, NCT04060017
  4. 8 Oct 2020: Trial started, NCT04060030

The trials

NCT04060017: Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium

State
Under way
Phase
Phase 2
People
80 planned
Started
22 Sep 2020
Primary completion
31 Jul 2026
Arms
L-leucovorin calcium
Results
None posted
  1. 16 Aug 2019: Trial registered
  2. 22 Sep 2020: Trial started

NCT04060030: Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism

State
Under way
Phase
Phase 2
People
80 planned
Started
8 Oct 2020
Primary completion
31 Jan 2027
Arms
L-leucovorin calcium
Results
None posted
  1. 16 Aug 2019: Trial registered
  2. 8 Oct 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Elvorine, Isovorin.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.